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Objectives: 
To identify  prognostic  factors  that  predict  the  risk  of  progression  of  renal  failure  in  adult 
patients at the time of diagnosis of primary focal and segmental glomerulosclerosis (FSGS) and to 
calculate cumulative renal survival rate based on identified factors.
ii
iii
Focal  and  segmental  glomerulosclerosis  (FSGS)  is  defined  as  a  clinical-
pathologic syndrome manifesting proteinuria, usually of nephrotic range, associated with 
lesions  of  focal  and  segmental  glomerular  sclerosis  and  foot  process  effacement. 
Although hyaline insudation is common, the condition lacks glomerular immune complex 
deposits.  Early  in  the  disease  process,  the  pattern  of  glomerular  sclerosis  is  focal, 
involving a subset of glomeruli, and segmental, involving a portion of the glomerular tuft. 
As  the  disease  progresses,  a  more  diffuse  and  global  pattern  of  sclerosis  evolves. 
Alterations of the podocyte cytoarchitecture constitute the major ultrastructural findings.
FSGS came to be viewed as a distinct pathologic entity by 1970. In recent years it 
has  become clear  that  FSGS is  seen  more  usefully  as  a  clinicopathologic  syndrome, 
comprising  diverse  distinct  diseases  with  different  etiologies.  These  include  genetic 
mutation (likely showing both Mendelian and non-Mendelian modes of inheritance), viral 
infection,  relative  overabundance  of  a  pathogenic  plasma  factor,  and  hyperfiltration 
injury. Doubtless, there are other disease entities within the FSGS syndrome that remain 
undefined.
Among  the  biopsy  proven  renal  disease  in  adults,  focal  and  segmental 
glomerulosclerosis is the commonest histological category in all  age groups (16.8%)1. 
Although the pathogenesis of primary focal and segmental glomerulosclerosis (FSGS) is 
unknown,  it  is  one  of  the  most  common  causes  of  primary  glomerular  disease  that 
terminate  in  end stage  renal  disease  (ESRD).  In  most  series,  the  10-year  survival  is 
between 40-60%.2-5 
Various studies have shown that clinical, biochemical and pathological indicators 
can help to predict renal failure in a patient with FSGS. These are age at the time of 
presentation, gender, amount of proteinuria, hypertension, renal dysfunction, percentage 
of  sclerosed  glomeruli  and  interstitial  fibrosis,  location  of  segmental  sclerosis  and 
therapeutic  response  to  steroids6,7.  Whether  these  prognostic  factors  and  survival  rate 
mentioned in the western literature are relevant to Indian population is unknown. 
In the present study, we analysed the clinical, laboratory, and histopathological 
data of adult patients with biopsy proven FSGS over 10 years to identify risk factors at 
diagnosis associated with progression and to determine survival rates. 
 
Fahr (1925) showed that patients with lipoid nephrosis who progressed to renal 
failure showed focal glomerular damage. Rich (1957) examined autopsy tissue from 20 
children with nephrotic syndrome and otherwise typical lipoid nephrosis and described 
progressive  sclerosis  of  glomeruli,  affecting  first  the  juxtamedullary  glomeruli. 
McGovern (1964) and Hayslett et al8 (1969) showed that in some patients whose initial 
biopsy examination showed minimal changes, a later biopsy examination showed focal 
sclerosing glomerulonephritis. Churg et al9  (1970), writing for the International Study of 
Kidney Disease in Children, described biopsy examination findings in 127 children with 
nephrotic syndrome and found that focal sclerosing glomerular lesions were the second 
most common finding, after minimal changes.
The  diagnosis  of  FSGS  is  complicated  by  the  existence  of  a  primary  (or 
idiopathic)  form and  many secondary  forms.  Secondary  FSGS caused  by  structural-
functional adaptations mediated by intrarenal vasodilatation and by increased glomerular 
capillary pressures and plasma flow rates. Such maladaptive glomerular hemodynamic 
alterations can arise through: (1) a reduction in the number of functioning nephrons (such 
as after unilateral renal agenesis, surgical ablation, oligomeganephronia, or any advanced 
primary renal disease), or (2) mechanisms that place hemodynamic stress on an initially 
normal nephron population (as in morbid obesity, cyanotic congenital heart disease, and 
sickle cell  anemia).  Finally,  primary and secondary FSGS also must be differentiated 
from the nonspecific pattern of focal and segmental glomerular scarring that can follow a 
variety of inflammatory, proliferative, thrombotic, and hereditary conditions.
Table 1  .  Etiologic Classification of FSGS  
Primary (idiopathic) FSGS
C1q nephropathy
HIV-associated nephropathy
Heroin nephropathy
Familial FSGS
   Mutations in α-actinin 4 (autosomal dominant)
   Mutations in podocin (autosomal recessive)
   Mitochondrial cytopathies
Drug toxicity
   Pamidronate
   Lithium
   Interferon-α
Secondary FSGS 
   Reduced renal mass
      Oligomeganephronia
      Unilateral renal agenesis
      Renal dysplasia
      Reflux nephropathy
      Sequela to cortical necrosis
      Surgical renal ablation
      Any advanced renal disease with reduction in functioning nephrons
      Chronic allograft nephropathy
   Initially normal renal mass
      Diabetes mellitus
      Hypertension
      Obesity
      Cyanotic congenital heart disease
      Sickle cell anemia
Nonspecific pattern of FSGS caused by renal scarring
   Focal proliferative glomerulonephritis (IgA nephropathy, lupus nephritis,etc)
   Hereditary nephritis
   Diabetic nephropathy
   Hypertensive arterionephrosclerosis
   Membranous glomerulopathy
   Thrombotic microangiopathies
Pathologic Classification:
FSGS comprises a number of morphologic subtypes that may have different 
prognostic and therapeutic implications. These morphologic variants were defined at a 
recent consensus conference of renal pathologists in New York City. 
FSGS not otherwise specified (NOS) constitutes the generic lesion of FSGS. The 
synonyms classic FSGS or FSGS of the usual type often are applied. This category 
requires that other morphologic categories (perihilar, cellular, tip, and collapsing) be 
excluded. FSGS (NOS) is the most common morphologic pattern of FSGS. Evidence 
from repeat biopsy examinations suggests that other variants may evolve into this pattern 
in the course of disease progression and increasing chronicity.
Morphologically FSGS (NOS) is characterized by Lesions of sclerosis can affect 
the perihilar (ie, vascular pole) region or the periphery of the tuft. In some glomeruli, 
segmental  lesions  may affect  more  than  one  lobule,  involving  both  the  perihilar  and 
peripheral regions. According to one study using serial sections, peripheral lesions tend to 
be more common in childhood FSGS than the adult disease.10 Any number of glomeruli 
can be affected by segmental sclerosis, with or without associated global sclerosis. There 
may  be  segmental  glomerular  basement  membrane  collapse  without  podocyte 
hyperplasia.
By  immunofluorescence,  there  is  typically  focal  and  segmental  granular 
deposition  of  IgM,  C3,  and  more  variably  C1  in  the  distribution  of  the  segmental 
glomerular sclerosis and hyalinosis . More generalised weak  mesangial deposition of 
IgM also may be present.
By electron microscopy, the lesion of segmental sclerosis display wrinkling and 
retraction  of  glomerular  basement  membrane  and  accumulation  of  inframembranous 
hyaline, with resulting narrowing or occlusion of the glomerular capillary lumina.  The 
electron dense hyaline material is usually more waxy in appearance than true immune 
complex deposits and tends to pool beneath the GBM, conforming to the contours of the 
delimiting  membrane.  Endocapillary  foam  cells  appear  as  large  intracapillary  cells 
containing abundant electron lucent vacuoles. 
Directly overlying the lesions of segmental  sclerosis  there  usually is  complete 
effacement  of  foot  processes,  accompanied  by  podocyte  alterations  that  include 
hypertrophy, increased organellar  content,  and focal microvillous transformation.  This 
microvillous  appearance  is  caused  by  the  formation  of  slender  cellular  projections 
resembling  villi  along  the  surface  of  the  podocytes  facing  the  urinary  space.  The 
hypertrophied  podocytes  display  rounded  cell  bodies  that  adhere  smoothly  to  the 
glomerular basement membrane (GBM), with frequent loss of primary processes.
The major ultrastructural finding involving nonsclerotic glomerular capillaries is 
foot process effacement. The degree of foot process fusion observed overlying these open 
capillaries varies from mild to severe, but usually involves greater than 50% of the total 
glomerular capillary surface area. In general, the degree of fusion correlates roughly with 
the severity of the proteinuria, such that patients with subnephrotic proteinuria tend to 
have less foot process fusion than those who are fully nephrotic.  In the areas of foot 
process effacement, there usually is loss of recognizable slit  diaphragms and mat-like 
condensations of cytoskeletal  filaments oriented parallel  to  the direction of the GBM 
itself. Thus, although the lesions of FSGS are focal at the light microscopic level, the 
podocyte alterations are relatively diffuse at the electron microscopic level
FSGS perihilar variant category requires that the cellular variant, tip variant, and 
collapsing variant be excluded. It is defined by the presence of perihilar sclerosis and 
hyalinosis  involving  greater  than  50%  of  segmentally  sclerotic  glomeruli. 
Glomerulomegaly and adhesions  are  common.  Podocyte  hypertrophy and hyperplasia 
may be present but typically are less frequent than in the other variants. Other glomeruli 
may show lesions of segmental and/or global glomerulosclerosis, as described for FSGS 
(NOS) earlier. 
Perihilar  variant  of  FSGS  may  occur  in  primary  FSGS.  However,  when 
accompanied by glomerulomegaly, it is particularly common in patients with secondary 
forms  of  FSGS  mediated  by  an  adaptive  response  to  increased  glomerular  capillary 
pressures and flow rates (as in association with obesity, cyanotic congenital heart disease, 
reflux  nephropathy,  renal  agenesis,  dysplasia,  oligomeganephronia,  or  any  advanced 
renal disease with a reduced number of functioning nephrons). 
The cellular variant of FSGS was first described by Schwartz and Lewis in 1985. 
The cellular variant is defined by the presence of at least one glomerulus with segmental 
endocapillary hypercellularity involving at least 25% of the tuft and causing occlusion of 
the  capillary  lumen.  Any  segment  (perihilar  or  peripheral)  may  be  affected.  When 
numerous  glomeruli  are  affected,  the  process  may  mimic  focal  proliferative 
glomerulonephritis.11 
By immunofluorescence there is  focal and segmental  glomerular  positivity for 
IgM and C3. At the ultrastructural level, the cellular variant usually displays severe foot 
process effacement, correlating with the generally high levels of proteinuria . Cellular 
lesions  consist  of  segmental  occlusion  of  glomerular  capillaries  by  endocapillary 
hypercellularity  including  foam  cells  and  monocytes.  The  glomerular  basement 
membrane is intact, without evidence of rupture.
Compared with FSGS (NOS), the cellular variant is characterized by more severe 
proteinuria  and  a  shorter  time  course  from clinical  onset  of  renal  disease  to  biopsy 
examination,  suggesting  an  early  phase  in  the  evolution  of  the  segmental  sclerosis. 
Schwartz and Lewis found a shorter interval between onset of proteinuria (3.4 versus 
71.9 mo) in patients with cellular versus classic FSGS. Moreover, 90% of patients in the 
cellular group had urine protein levels greater than 3 g/d, compared with 49% of those 
without  cellular  lesions.  Similarly,  the  incidence  of  full  nephrotic  syndrome  at 
presentation  was significantly higher  (70% versus  23%).  Patients  with  cellular  FSGS 
often have a very abrupt onset of severe nephrotic syndrome
The  cellular  variant  may be  responsive  to  immunosuppressive  therapy.12 This 
favourable treatment response probably relates to the early and relatively active stage of 
glomerular injury in the cellular variant.
The tip variant of FSGS is defined by the presence of at least one glomerulus with 
a segmental lesion involving the tip domain (ie, the peripheral 25% of the glomerular tuft 
next to the origin of the proximal tubule). There must be either adhesion between the tuft 
and Bowman's capsule at the tubular lumen or neck, or confluence of podocytes with 
parietal epithelial or tubular epithelial cells at the tubular pole or neck.
Tip lesions may arise as a nonspecific response of the peritubular segment of the 
glomerular tuft to fluxes of protein-rich filtrate in the setting of nephrotic syndrome.
The designation of collapsing variant is applied to cases of FSGS in which at least 
one  glomerulus  displays  segmental  or  global  obliteration  of  the  glomerular  capillary 
lumina by wrinkling and collapse of GBMs associated with podocyte hypertrophy and 
hyperplasia. Collapse involving a single glomerulus is considered significant, such that 
the presence of any glomerular collapse pre-empts the other morphologic categories of 
FSGS.
There  are  2  pathologic  findings  that  together  define  the  collapsing  variant  of 
FSGS.13,14 First, there is implosive wrinkling and retraction of the GBM. Second, there is 
marked  hypertrophy  and  hyperplasia  of  overlying  visceral  epithelial  cells.  Visceral 
epithelial cells frequently contain protein resorption droplets and may appear detached 
from the underlying GBM. Lesions of collapsing FSGS often coexist in the same biopsy 
specimen with other patterns of FSGS, including cellular lesions and discrete segmental 
scars typical of the classic form of FSGS.
The changes seen in collapsing FSGS are not confined to glomeruli. There are 
typically widespread tubular degenerative changes including luminal ectasia, cytoplasmic 
simplification  and  vacuolization,  loss  of  brush  border,  nuclear  pleomorphism  with 
prominent  nucleoli,  and multiple  mitotic  and apoptotic  figures.  Proximal  tubules  also 
display protein resorption droplets. In almost half of cases, tubular microcysts are seen 
and typically display a proteinaceous filtrate that stains positively with the periodic acid 
Schiff  stain. Interstitial edema and a mild to moderate chronic inflammatory infiltrate 
characteristically accompany the tubular degenerative changes. Rare foci of mild tubulitis 
may be apparent. With progression of disease, tubular atrophy and interstitial  fibrosis 
intervene.
In  the  setting  of  collapsing  FSGS,  immunofluorescence  typically  reveals 
positivity for IgM and C3 in the distribution of the lesions of FSGS. The intensity of 
staining is typically trace to 1+ but may be up to 2+ (scale: 0, trace, 1-3+). Staining for 
IgG, IgA, and κ and λ light chains is negative.
Electron microscopy reveals an increase in the number and size of podocytes. On 
the  subcellular  level,  there  may  be  an  increase  in  organellar  content  and  transport 
vesicles, microvillous transformation, lipid and protein resorption droplets, and extensive 
foot  process  fusion.  Although  the  podocyte  changes  normally  are  diffuse,  glomeruli 
containing lesions of collapsing FSGS will display more prominent podocyte changes as 
well as wrinkling and retraction of the GBM. Within the capillary lumina, focal hyaline 
insudation and rare endocapillary foam cells may be apparent. Electron dense deposits 
typically  are  absent  although rare  mesangial  deposits  should  not  be a  deterrent  from 
making the diagnosis of collapsing FSGS.
Trends in the Epidemiology of FSGS: 
FSGS is  currently  a  leading  cause  of  nephrotic  syndrome in  adults.  Previous 
studies from the 1970s and early 1980s list FSGS as being responsible for 15% to 20% of 
cases of idiopathic nephrotic syndrome (NS) in adults.   Korbet et al15 found that among 
primary renal diseases, FSGS accounted for 29% of all adult patients presenting with 
nephrotic  range  proteinuria  between 1975 and 1985,  but  accounted  for  38% of  such 
patients  between  1985  and  1994.  Hass  et  al  also  observed  similar  increases  in  the 
proportion  of  FSGS  in  adults  undergoing  a  biopsy  examination  for  proteinuria  or 
nephrotic  syndrome.16 The  incidence  of  FSGS as  a  cause  of  end-stage  renal  disease 
(ESRD) also is increasing. The increase in the fractional contribution of FSGS to the 
etiology  of  primary  nephrotic  syndrome  could  also  be  caused  by  changes  in  the 
demographics  of  patients  undergoing  renal  biopsy  examinations  or  a  decline  in  the 
incidence  of  other  diseases  such  as  membranous  glomerulopathy  or  minimal  change 
disease. 
Racial background has a strong influence on the propensity to develop FSGS. Black subjects have 
an increased risk for idiopathic FSGS, as has long been recognized.17 In a logistic regression analysis of 
adult patients with nephrosis, race remained the only significant predictor for FSGS, with black subjects 4 
times more likely to have FSGS than white subjects. Black individuals are also at increased risk for Human 
immunodeficiency  virus  (HIV)-associated FSGS.18 Occult  HIV  infection  is  unlikely  to  explain  the 
increasing  frequency  of  FSGS.  Although  screening  for  HIV  is  often  not  performed  in  patients  with 
glomerulonephritis, most studies that show an increasing incidence of FSGS in black individuals exclude 
patients with known HIV, intravenous drugs usage, or the presence of tubuloreticular structures. In at least 
one study with serologic testing for HIV, a high frequency of idiopathic FSGS also was shown in black 
subjects. Other infectious agents such as parvovirus B1919and SV4020 have been linked to the development 
of FSGS. Whether these viruses or other as yet unknown infectious agents may contribute to the increasing 
occurrence of FSGS in susceptible populations is yet to be determined.
Another consideration is the increase in the collapsing variant of FSGS. Barisoni 
et  al21 found an  increasing  incidence  of  FSGS with  collapsing  features  among HIV-
negative patients. This entity was not seen before 1979 and has more than doubled from 
11% of all idiopathic FSGS between 1979 and 1985 to 24% from 1990 to 1993. The 
same group found that patients with collapsing FSGS were predominantly of black race. 
The median renal survival from time to biopsy examination to end stage renal disease 
was shorter in the collapsing group (13 mo) compared with the other FSGS group (63 
mo). Other investigators confirmed the higher incidence of the collapsing variant in black 
subjects  and the poor  renal  outcome associated with this  condition.22 However,  these 
investigators reported that the collapsing variant only accounted for 4% of all FSGS and 
the number of cases did not increase with time. These discordant findings may be owing 
to  differences  in  case  definition  or  true  population  differences.  Because  of  its  rapid 
progression to renal failure, the collapsing variant likely contributes disproportionately to 
the FSGS patients reaching end stage kidney disease. This may in part account for a 
higher incidence of black subjects with FSGS end stage renal disease. 
Genetic Basis of FSGS:
The role of genetic factors in the development of FSGS in humans has become 
increasingly apparent in recent years. Genetic studies also have helped strengthen the 
notion that glomerular visceral epithelial cell (or podocyte) disorders lead to a spectrum 
of clinical presentations, from congenital nephrotic syndrome (CNF), to minimal change 
disease (MCD), and FSGS. Four siblings with nephrotic syndrome were described in a 
1957  report.  Pathology  showed  minimal  change  disease  in  some  children,  FSGS  in 
others. The absence of disease in the parents suggested recessive inheritance. Additional 
scattered reports of both single-generation and multigeneration disease have continued to 
appear in the case literature.24
Congenital nephrotic syndrome of the Finnish type, or CNF, is a geographically 
widespread disease characterized by the development of severe nephrosis in utero and 
autosomal-recessive inheritance. Affected neonates have on the order of 20 to 30 g/d 
proteinuria and typically die from complications of the nephrotic syndrome at a young 
age.  Subsequent  to  mapping  the  CNF gene  to  chromosome 19q13  by a  means  of  a 
genome-wide linkage analysis, the CNF gene NPHS1 was cloned by positional methods. 
Nephrin, the gene product, is a 185-kd protein containing a fibronectin III-like domain, 8 
immunoglobulin C2 motifs, and a single transmembrane segment. Nephrin localizes to 
the slit diaphragm in the podocyte. Nephrin appears to play a role in regulating signaling 
pathways.25 
Most of the congenital nephrotic syndrome in Finland is caused by 2 specific NPHS1 
mutations, Fin major (the deletion of nucleotides 121-122 leading to a frameshift) and Fin 
minor (encoding a premature termination signal at amino acid 1109). The incidence of 
CNF is 1 in 500 live births in this group.
The identification of NPHS1 has improved the antenatal diagnosis of CNF. 
Fuchshuber  et  al described  a  form  of  nephrosis  characterized  by  recessive 
transmission, early onset, resistance to steroid therapy, and rapid progression to end-stage 
kidney failure. The majority of the affected children showed an FSGS pattern on renal 
biopsy. The gene for this recessive form of FSGS was mapped to chromosome 1q25-31 
and subsequently cloned. NPHS2, the responsible gene, encodes podocin, a 383 amino 
acid integral membrane protein.
Autosomal-dominant forms of FSGS typically present later and are more slowly 
progressive than recessive forms. Mutations in ACTN4, encoding α-actinin-4, cause a 
slowly progressive form of disease with dominant inheritance, nonnephrotic proteinuria, 
and renal  insufficiency.  The penetrance of ACTN4-associated disease is  high but  not 
100%. ACTN4 is the only actinin expressed significantly in the human glomerulus. The 
ACTN4 mutations identified in FSGS families are all missense and increase the affinity 
of the encoded protein to actin filaments. 
FSGS also is seen as part of well-defined inherited syndromes. The spectrum of 
disease seen with WT1 mutations is the best studied of these disorders. Frasier syndrome 
and Denys-Drash syndrome are related and overlapping syndromes caused by mutations 
in WT1. Both syndromes are characterized by glomerular disease and the development of 
male pseudohermaphroditism. 
Frasier syndrome is caused by donor splice mutations in intron 9 of WT1. Frasier 
syndrome  can  present  as  FSGS  in  46,  XX  females  in  association  with  gonadal 
malignancy.26,27
 Denys-Drash syndrome is defined by diffuse mesangial sclerosis on renal biopsy 
examination, genitourinary tumors, and pseudohermaphroditism. A different spectrum of 
mutations is seen in Denys-Drash syndrome, most commonly within exon 9 of WT1.28  
 Nail-Patella  syndrome  generally  is  regarded  as  a  disease  of  the  basement 
membrane rather than the podocyte, though it is probably both. An altered glomerular 
basement membrane typically predominates on histologic analysis, the glomerulopathy is 
variable and can present as nephrotic syndrome. Defects in the lmx1b transcription factor 
are responsible for disease. Lmx1b helps control the transcriptional regulation of matrix 
proteins by the podocyte as well as the podocyte genes CD2AP and NPHS2.
Permeability Factors in FSGS:
The  theory  that  idiopathic  nephrotic  syndrome,  minimal  change  nephrotic 
syndrome (MCNS) or FSGS represents “a systemic abnormality in lymphocyte function 
resulting in the secretion of a circulating chemical mediator toxic to an immunologically 
innocent glomerular basement membrane” was proposed formally by Shalhoub29 in 1974. 
This proposal was based on the absence of evidence for a humoral antibody response, on 
clinical remissions after treatment with steroids or cyclophosphamide and after measles 
infection,  and  on  the  occurrence  of  nephrotic  syndrome  in  patients  with  Hodgkin's 
lymphoma. The presence of a circulating factor in FSGS was proposed by Hoyer et al30 
after they observed that nephrotic proteinuria recurred promptly after transplantation of a 
normal kidney into a recipient who had FSGS as the cause for renal failure. This idea was 
supported by the observation of Zimmerman31 that injection of serum from a patient with 
recurrent FSGS into the aorta of a rat resulted in an immediate onset of proteinuria and 
albuminuria.  No proteinuria  occurred after  infusion of  sera  from a patient  with  prior 
FSGS but no posttransplant recurrence or from 10 patients with other forms of nephrotic 
syndrome.  Treatment  of  patients  with  recurrent  FSGS  in  renal  allografts  with 
plasmapheresis,  immunoadsorption,  or low-density lipoprotein apheresis may result  in 
decreased proteinuria and prolongation of allograft survival. 
Work  to  clarify  the  relationship  of  a  circulating  proteinuric  factor  to  FSGS 
remained dormant until the early 1990s when seminal observations from several centers 
provided strong evidence that an etiologic factor was present in a number of patients with 
recurrent  FSGS.  In  1994,  Savin  et  al  reported  that  incubation  in  medium containing 
serum or plasma from patients with recurrent FSGS increased albumin permeability (Palb) 
of glomeruli isolated from normal rats and that the capacity to increase Palb was reduced 
by plasmapheresis.32,33 During that same year, other investigators reported that injection 
of eluate obtained from plasma of patients with recurrent FSGS and eluted from protein 
A-immunoadsorbent  material  induced  albuminuria  in  rats.34 In  vitro  testing  using 
functional assays of permeability based on glomerular volumetric responses to oncotic 
gradients has been essential to understand the role of permeability factors in FSGS. 
The mechanism by which the FSGS factor increases glomerular albumin permeability in vitro or 
in vivo remains to be elucidated. Increased glomerular albumin permeability after 10 min of incubation in  
vitro raises  the possibility  that  the FSGS factor interacts  with  membrane  components of  the exposed 
glomerular epithelial cells. Glomerular epithelial cells have been shown to play a crucial role in maintaining 
the filtration barrier.  The magnitude of  the effect of  FSGS sera on glomerular permeability  in vitro was 
comparable  to  that  of  anti-Fx  1a  antibody, superoxide,  hydroxyl  ion,  or  tumor  necrosis  factor  α.  The 
rapidity of increase in glomerular permeability suggests that  the immediate effect of  the FSGS factor is 
unlikely to be mediated by metalloproteinase-3 or through charge neutralization by protamine35, as  these 
agents required prolonged incubations of more than 4 h and 1 h, respectively.
It  appears  that  the  mechanism  by  which  the  FSGS  factor  increases  glomerular  permeability 
depends on active cellular metabolism rather than charge neutralization. This conclusion is based on the 
rapidity of the response, the small quantity of the FSGS factor required, its anionic rather than cationic 
charge, and the fact that a number of inhibitors prevent the increase in permeability. The mechanism that is 
most clearly documented relies on the action of cyclooxygenase. The permeability barrier is preserved by 
the inclusion of indomethacin or the thromboxane synthase inhibitor furegrelate in the incubation medium. 
Several eicosanoids increase Palb including PGE2, PGF2α, and a thromboxane A2 mimetic.
Hyperfiltration and Glomerulosclerosis: 
In  1932,  Chanutin  and  Ferris  described  proteinuria  and  progressive 
glomerulosclerosis  after  major  reductions  in  renal  mass  in  the  rat.  Subsequent 
investigators, notably Shimamura and Morrison, further characterized the experimental 
disease of the remnant kidney using ultrastructural approaches and described fusion of 
epithelial  cells  as  well  as  glomerular  enlargement.  Olson  et  al36 further  detailed  the 
cellular  and permselective responses,  documenting detachment  of podocytes  from the 
basement membrane and loss of filtration size selectivity. These studies all used high 
degrees of subtotal renal ablation to induce injury in the remnant glomeruli. Others have 
shown a graded response to removal of kidney parenchyma with even lesser degrees of 
reduction accelerating damage but  at  a  slower rate  and with less  severe damage. For 
example, even simple unilateral nephrectomy leads to an increased pace of sclerosis in 
remaining kidneys. With loss of renal tissue and before they sustain pathologic changes, 
the  remaining  nephrons  undergo  a  process  conventionally  termed  compensatory 
hyperfunction, whereby their  single nephron filtration rates increase and the nephrons 
grow. The notion arose that this increase in single nephron filtration or hyperfiltration, 
though compensatory in the short term, caused subsequent pathology.
In humans, simple unilateral nephrectomy in otherwise healthy individuals seems 
to lead to little in the way of adverse renal consequences. Perhaps the most complete 
study is one of men who lost a kidney owing to trauma during World War II. When these 
people were followed-up 45 years later, no increase in renal disease, hypertension, or 
proteinuria could be discerned. Furthermore, in a subset for whom autopsy tissue was 
available, no increased prevalence of glomerular injury was notable. As the investigators 
cautioned, these servicemen were largely of European ancestry and healthy at the time of 
their initial loss of a single kidney. However, reviews of individuals who have donated a 
kidney  for  transplantation  have  in  general  revealed  no  substantial  long-term 
consequences.  The  donors  were,  of  course,  screened  for  serious  underlying  kidney 
disease or conditions predisposing to a renal injury. On the other hand, some suggestions 
that losses of renal mass perhaps at susceptible periods of development or in susceptible 
individuals may be associated with subsequent injuries have been recorded. For example, 
unilateral renal agenesis is a relatively rare congenital condition but it has been associated 
with  serious  proteinuria  and  sclerosis  of  the  single  kidney  as  an  individual  ages. 
Conceivably in this circumstance, the solitary kidney has subtle developmental defects 
that render it susceptible to injury. Likewise, progressive damage to the remaining kidney 
after removal of a contralateral diseased kidney may just reflect unrecognized bilateral 
disease. However, with more extreme renal surgery, injury may be seen in humans. One 
study of subtotal nephrectomy sustained owing to aggressive renal cancer surgery has 
suggested  that  sclerotic  injury  develops  in  the  spared  but  hypertrophied  glomeruli. 
Perhaps as in the animal studies, some variations occur among different groups of people 
and susceptibility to loss of renal mass may be more pronounced in some individuals.
Fairly wide variation in the number of nephrons has been noted in human adult 
kidneys. Given the general trend, at least in animal studies, for lesser nephron number to 
lead to greater single nephron filtration rate and greater propensity for injury, Brenner 
and  Mackenzie  have  argued  that  individuals  with  natively  fewer  nephrons  are 
predisposed to renal disease, hypertension, and glomerular sclerosis. The concept fits in 
part  with  Osmond's  and  Barker's  hypothesis  that  lower  birth  weights  predispose  to 
cardiovascular disease in later life.
The potential for glomerular capillary pressures to induce progressive sclerotic 
injury seems clear. Numerous studies have implicated all 3 of the major glomerular cell 
types in this process. Because of their similarities to vascular smooth muscle cells, which 
have vigorous responses to arterial hypertension, and because of the prominent mesangial 
abnormalities  with  hyperfiltration,  investigators  have  focused  on  the  mesangial  cell's 
response to altered glomerular hemodynamics.
Mesangial cells, when grown in culture on a pliable matrix, proliferate in response 
to stretching. This model simulating increased glomerular tension displays, in addition to 
cellular  hyperplasia,  increased  production  of  matrix  substances  such  as  collagens, 
laminin, and fibronectin. Cells along the periphery of cyclically stretched membranes, 
where deformation is most pronounced, develop the greatest degree of proliferation and 
matrix  production.  This  finding  further  supports  the  view  that  increased  physical 
stretching of the mesangial cells contributes to responses reminiscent of the fundamental 
processes of sclerosis in vivo
A series of events involving podocyte failure have been proposed by Kriz et al. 
These  investigators  have suggested  that  in  the course  of  a  hemodynamically induced 
sclerosis, the failure of the mesangial cells to provide a tethering function to the overlying 
basement  membrane  in  conjunction  with  podocyte  insufficiency  bares  basement 
membrane, which provides not only an egress for protein, but also a point at which the 
parietal epithelial cells may adhere to this exposed basement membrane.
After these seemingly adaptive increases in function, pathologic changes appear, 
eventuating in glomerular sclerosis. Among the determinants of increased single-nephron 
filtration after renal mass reduction, the increase in glomerular capillary pressure seems 
to be pre-eminent in aggravating the progressive sclerotic changes. Actions of the renin-
angiotensin-aldosterone system probably underlie many of these hemodynamic changes. 
Other  vasoactive  systems  also  are  likely  to  exert  actions  in  the  process  but  no  one 
element  of  these systems has  yet  proven to  be a  necessary component  of heightened 
pressures.  Various  cellular  responses  follow  from these  higher  glomerular  pressures, 
especially  in  association  with  the  hypertrophy  of  the  glomerular  unit.  Changes  in 
mesangial  cell  function,  relative  deficiency  of  podocytes,  and  perhaps  endothelial 
generation  of  vasoactive  and fibroproliferative  cytokines,  all  have  been  linked in  the 
chain connecting hemodynamic changes with glomerular sclerosis.
Human Immunodeficiency Virus (HIV) and FSGS: 
Human  immunodeficiency  virus-associated  nephropathy  (HIVAN)  was  first 
described  by  Rao  et  al37 in  1984  in  10  patients  with  acquired  immune  deficiency 
syndrome  who  developed  a  rapidly  progressive  renal  disease.  These  patients  had 
moderate  to  massive  proteinuria  and all  developed end-stage  renal  disease  within  16 
weeks. Biopsy examinations revealed focal segmental glomerular nephritis. Six of the 11 
patients  had  no  known risk  factors  for  renal  disease,  and  the  association  was  made 
between infection with HIV-1 and a characteristic nephropathy.
The classic pathologic lesion of HIVAN is focal segmental  glomerulosclerosis 
with  collapse of  the  glomerular  tuft,  associated with dilated tubules  with microcysts. 
Tubuloreticular inclusions, once commonly observed by electron microscopy in as many 
as 25% of patients, has become a rare finding, possibly owing to more effective therapy. 
Clinically,  HIVAN  patients  present  with  heavy  proteinuria  and  hypoalbuminemia. 
HIVAN patients also typically are normotensive. The absence of hypertension may be the 
result of a tubular defect in fluid and electrolyte handling. Ultrasound shows enlarged, 
echogenic  kidneys.  The  degree  of  azotemia  varies,  but  HIVAN  always  has  been 
characterized by a rapid deterioration of renal function. 
In early studies of the natural history of HIVAN, time from diagnosis of HIVAN 
to initiation of hemodialysis was reportedly from weeks to months, with most patients 
dead  within  a  year. More  recent  data  show  that  despite  improved  survival  of  HIV-
seropositive patients in general, patients with ESRD secondary to HIVAN have higher 
mortality rates than those with ESRD of other causes. In a review of USRDS data from 
1992 to 1997, 2-year survival was 36% for patients with HIVAN compared with 64% for 
all other patients with ESRD. HIVAN initially was believed to be a late manifestation of 
acquired immune deficiency syndrome because it  appeared in patients  with low CD4 
counts and a history of opportunistic infections. There are now reported cases, however, 
of HIVAN developing in patients at the time of seroconversion, indicating that it also 
may present early in the course of HIV.38,39   
Renal  biopsy  examinations  of  patients  have  shown  both  proliferative  and 
apoptotic changes. The primary process is uncertain, but because kidneys are enlarged, 
proliferation is most likely the predominant process.
Transforming  growth  factor-β  (TGF-β)  is  a  fibrogenic  cytokine  that  regulates 
human immune function and has been shown to regulate HIV replication. A study of 
human kidneys  found increased deposition of matrix proteins and increased levels  of 
TGF-β in those kidneys with HIVAN compared with normal kidneys and with kidneys 
with thin basement membrane and minimal change nephropathies. This was true even 
when compared with kidneys of HIV infected individuals without HIVAN.40 
In a study comparing HIV transgenic mice with normal mice, transgenic kidneys 
had  increased  basic  fibroblast  growth  factor  (bFGF)  and  a  greater  number  of  bFGF 
binding  sites.  Transgenic  tubular  epithelial  cells  were  found  to  express  bFGF  and 
transgenic epithelial cells or nontransgenic cells treated with bFGF exhibited an increased 
rate of proliferation compared with controls.41 
Renal mesangial cell cultures incubated in sera collected from HIV-seropositive 
patients showed a greater degree of proliferation than those cells incubated in normal 
control sera. This effect was concentration dependent, and was inhibited in the presence 
of azidothymidine 
Renal epithelial cells of transgenic mice42 and biopsy specimens from a human 
subject with HIVAN43 showed an increased expression of markers of proliferation such as 
the  Ki-67  antigen,  and  a  decreased  expression  of  markers  of  differentiation  such  as 
synaptopodin. 
Collapsing Glomerulopathy or Malignant FSGS:
Collapsing glomerulopathy, also known as collapsing FSGS or malignant FSGS, 
initially was described as a distinct clinicopathologic entity in 1986, when Weiss et al44 
reported a group of 6 patients with nephrotic syndrome, rapidly progressive renal failure, 
and glomerular collapse. Renal biopsy examination displayed the characteristic features 
of  collapsing  glomerulopathy:  segmental  and  global  collapse  of  the  glomerular 
capillaries, wrinkling and retraction of the glomerular basement membrane, and marked 
hypertrophy  and  hyperplasia  of  podocytes.  Tubulointerstitial  changes  also  were 
prominent  and  included  tubular  dilatation  and  degeneration,  epithelial  necrosis,  and 
interstitial  fibrosis and edema. In this  initial  report,  all  6 patients  were black,  and all 
presented with nephrotic syndrome and varying degrees of renal insufficiency. Five of 
the  6 patients  also  had  a  nonspecific  febrile  illness  before  presentation,  but  no clear 
etiologic factor was identified. 
Most cases of collapsing glomerulopathy are either HIV-associated or idiopathic. 
In addition, a secondary cause of collapsing glomerulopathy is treatment with high-dose 
pamidronate, a bisphosphonate used to treat osteolytic bone lesions and hypercalcemia of 
malignancy. In 2001, 7 patients who were white, HIV negative, and developed collapsing 
glomerulopathy after treatment of multiple myeloma or breast cancer with pamidronate 
were reported. Patients were treated with pamidronate for 15 to 48 months before renal 
biopsy examination, and 5 of the 7 had received more than the recommended dosage of 
90 mg intravenously per month. All patients developed renal insufficiency and nephrotic 
syndrome, with a mean creatinine level of 3.6 mg/dL and a mean 24-hour urinary protein 
excretion of  12.4 g/d.  Three of  5 patients  in  whom pamidronate  was  withdrawn had 
stabilization of their renal function.45 The same group later reported a case of collapsing 
glomerulopathy in which the patient's proteinuria significantly decreased after withdrawal 
of pamidronate but then worsened with reintroduction of this agent.75 Since the original 
report  of  7  patients,  10  additional  cases  of  pamidronate-associated  collapsing 
glomerulopathy have been seen.46 Other centers also have reported cases of FSGS and 
collapsing glomerulopathy after treatment with pamidronate.47,48
Recent studies and case reports have suggested an association between collapsing 
glomerulopathy and parvovirus B19 infection.49 This association is intriguing given the 
establishment of HIV as a  viral  cause of collapsing glomerulopathy and the frequent 
reports  of  a  nonspecific  febrile  illness  before  the  development  of  collapsing 
glomerulopathy.  One  study of  40  patients  by  Tanawattanacharoen  et  al19 reported  a 
significantly  greater  prevalence  of  parvovirus  B19  DNA  by using  polymerase  chain 
reaction in patients with idiopathic FSGS and collapsing glomerulopathy compared with 
patients with membranous nephropathy and minimal change disease. A second study by 
Moudgil et al50 analyzed biopsy specimens of 23 patients with collapsing glomerulopathy 
for parvovirus B19 DNA by using polymerase chain reaction and compared the results 
with biopsy specimens of classic FSGS, HIVAN, and controls with other renal diseases. 
Parvovirus  B19  DNA  was  detected  in  78.3%  of  biopsy  specimens  with  collapsing 
glomerulopathy. This data suggest that infection of renal epithelial cells by parvovirus 
B19 may be an etiology of collapsing glomerulopathy in susceptible patients.  
Glomerular visceral epithelial cell injury underlies the pathogenesis of collapsing 
FSGS. Podocyte injury is characterized by increased cell turnover and reversion to an 
immature state. In a study of 8 patients with collapsing glomerulopathy, Bariety et al51 
showed  that  podocytes  detach  from  the  GBM,  lose  their  normal  podocyte  markers 
(vimentin,  podocalyxin,  and CR1),  and acquire macrophage-associated epitopes (KP1, 
PG-M1, and M 18). Barisoni et al52 studied the expression of podocyte maturity markers 
(WT-1,  CALLA,  C3b  receptor,  GLEPP-1,  podocalyxin,  synaptopodin)  and  the 
proliferation marker Ki-67 in 10 cases of idiopathic collapsing glomerulopathy, 8 cases 
of HIVAN, 5 cases of membranous nephropathy, and 5 cases of minimal change disease. 
In patients with idiopathic collapsing FSGS and HIVAN (but not in patients with other 
glomerular  diseases),  decreased  expression  of  podocyte  markers  of  maturity  and 
increased  expression  of  Ki-67  was  observed.  This  data  suggests  that  both  idiopathic 
collapsing  glomerulopathy  and  HIVAN  are  associated  with  a  dysregulated,  cycling 
podocyte phenotype.
In  collapsing  glomerulopathy,  expression  of  cyclin  A  (a  positive  cell  cycle 
regulatory  protein) is  increased while expression of synaptopodin,  cyclin D1, and the 
negative cell cycle regulatory proteins p27 and p57 are decreased.53 Shankland et al54 
evaluated a series of 9 patients with collapsing glomerulopathy, 16 patients with HIVAN, 
and 37 patients with other causes of nephrotic syndrome. Expression of p27 and p57 was 
uniformly decreased in collapsing glomerulopathy, cellular FSGS, and HIVAN.
Clinical Presentation and Course: 
FSGS presents with nephrotic syndrome, defined variably by the classic tetrad of 
proteinuria, hypoalbuminemia, edema, and hypercholesterolemia, or by the presence of 
edema  and  nephrotic-range  proteinuria..  However,  a  significant  number  of  patients 
present  with  isolated  proteinuria  or  with  proteinuria  and  hematuria.  The  cause  of 
proteinuria  is  uncertain.  As is  true for minimal  change nephrotic syndrome (MCNS), 
proteinuria  in  FSGS  occurs  without  apparent  disruption  of  the  glomerular  filtration 
barrier  sufficient to account for the massive protein loss.  Both MCNS and FSGS are 
described  as  showing  decreased  staining  for  glomerular  polyanion,  one  possible 
explanation  for  urinary  loss  of  albumin,  a  negatively  charged  protein.  Guasch  et  al 
describe  a  biphasic  curve  for  glomerular  permselectivity  in  patients  with  FSGS that 
includes decreased fractional clearance of smaller molecules, similar to what is observed 
in MCNS, but also increased fractional clearance of larger macromolecules, suggesting 
the existence of a shunt mechanism for the clearance of larger proteins. Urinary proteins 
may include,  in  addition to albumin,  other  components  of the plasma that  may have 
clinical significance. These include IgG and opsonizing factors, whose loss may lead to 
susceptibility to infection by encapsulated bacteria; vitamin D-binding proteins and 25-
OH-vitamin  D3,  causing  bone  demineralization;  and  iron-binding  proteins,  leading  to 
anemia.
An important consideration in the presentation of FSGS is the presence or absence 
of the nephrotic syndrome. In children, a survey of several studies indicates that as many 
as  80%  of  patients  are  nephrotic  at  presentation.  In  adults,  the  percentage  may  be 
somewhat lower. In a more recent retrospective study, adults were less likely to present 
with  nephrotic  syndrome  than  were  children  (55%  versus  76%),  but  over  time  the 
incidence  of  nephrosis  increased  to  greater  than  80%  in  both  groups.23 It  has  been 
suggested that patients presenting with nephrosis are more likely to progress to chronic 
kidney failure. Nephrotic patients are more likely to be hypertensive, to have increased 
serum creatinine levels, or to have hematuria. Hypertension and azotemia also are more 
likely in adults than in children. Although these findings may help define a population of 
patients, they are not useful for determining whether a patient has FSGS or is likely to 
progress to renal failure. The only valid diagnostic determinant is the biopsy examination 
itself. 
In the absence of nephrosis, FSGS may be found in as many as 30% to 50% of 
adult patients undergoing a biopsy procedure.5
 The presenting feature in all patients with primary FSGS is proteinuria, frequently 
resulting in the nephrotic syndrome, but a nonnephrotic presentation is not unusual in up 
to  25%  of  adults. In  addition,  hypertension,  and  renal  insufficiency  are  common 
presenting features. The presentation for patients with primary FSGS may differ among 
the histologic variants. In contrast to patients with classic FSGS, patients with the cellular 
or collapsing lesion are more often black, have more advanced renal insufficiency, and 
more severe proteinuria at presentation.55,56 Massive proteinuria (>10 g/d) at presentation 
is much more common among patients with the cellular lesion compared with patients 
with classic FSGS (70% versus 10% of patients).
The degree of proteinuria at presentation is one of the most important prognostic 
features in patients with primary FSGS.2,4,5  Nephrotic patients with primary FSGS reach 
ESRD over 5 to 10 years,4,5 and those patients with massive proteinuria (>10 g/24 h) have 
an even more malignant course with essentially all patients progressing to ESRD within 5 
years. This is in contrast to the more favorable prognosis in patients with nonnephrotic 
proteinuria  in  whom  a  renal  survival  of  over  80%  is  observed  after  10  years.4,6 
Additionally,  the level  of  serum creatinine at  presentation is  prognostic  with patients 
having a serum creatinine level greater than 1.3 mg/dL manifesting a significantly poorer 
renal survival than those with a level of 1.3 mg/dL or less.4,6 Of the various pathologic 
features that  have been studied,  the histologic feature that has most consistently been 
predictive  of  a  poor  prognosis  is  the  presence  of  advanced  (>20%)  interstitial 
fibrosis.6,58,59 Recent  studies  have  now  shown  the  presence  of  the  cellular  lesion  is 
associated with a significantly more rapid course to ESRD than that of classic FSGS.
The  presentation  and  course  of  patients  with  FSGS  secondary  to  conditions 
resulting from hyperfiltration or  functional  adaptations  such as reflux nephropathy or 
morbid obesity may differ somewhat from that of primary FSGS. Unlike patients with 
primary FSGS, those with secondary FSGS often present with a more indolent course and 
rarely have hypoalbuminemia and nephrotic syndrome despite having nephrotic range or 
even  massive  proteinuria.60,61 In  a  series  of  71  patients  with  obesity-related  FSGS, 
Kambham et al60 found that though 47% of obese patients presented with nephrotic range 
proteinuria only 7% had nephrotic syndrome compared with patients with primary FSGS 
in  whom  66%  of  patients  had  nephrotic  range  proteinuria  and  54%  had  nephrotic 
syndrome. On renal biopsy examination, patients with FSGS caused by obesity, as well 
as those caused by reduced nephron mass, reflux nephropathy, or sickle cell disease, were 
found to  have  glomerulomegaly (over  30% greater  diameter)  and less  extensive  foot 
process fusion than those patients with primary FSGS.60-62 Finally, despite similar degrees 
of renal insufficiency at presentation, patients with secondary FSGS have a less rapidly 
progressive course with a 5-year renal survival of approximately 80% compared with 
50% for patients with primary FSGS.61
In primary FSGS, remission of proteinuria best predicts a favorable outcome in 
nephrotic patients.59,63  Less than 15% of patients entering a complete remission progress 
to ESRD, whereas up to 50% of persistently nephrotic patients progress to ESRD over 5 
years.
Even a partial remission is associated with a less rapid decline in renal function as 
compared  with  patients  in  whom  the  nephrotic  syndrome  persists.5 Unfortunately, 
spontaneous remissions are rare, occurring in less than 5% of nephrotic patients with 
primary FSGS. However, patients receiving a course of treatment with steroids are 4 to 10 
times more likely to enter a remission than untreated patients.59 Because no clinical or 
histologic  feature  at  presentation  allows  one  to  predict  which  patients  will  enter  a 
remission, the response to a course of treatment becomes the best clinical indicator of 
outcome.63 
The  Southwest  Pediatric  Nephrology  Study  Group  reported  that  a  significant 
number of children with FSGS retained normal or near-normal function several  years 
after diagnosis. The absence of nephrosis may be a highly favorable index of disease 
activity. In one study, 47% of nephrotic adults progressed to end-stage kidney disease 
within  10  years,  whereas  only  8%  of  patients  who  were  not  nephrotic  similarly 
progressed.64 Regardless  of  the  conclusions  of  these  studies,  because  patients  with 
asymptomatic  proteinuria  without  nephrosis  subsequently  may  become  nephrotic  or 
progress to end-stage without becoming nephrotic, it is not possible to predict outcome 
confidently from the symptoms at presentation.
Treatment of FSGS:
The use of angiotensin converting enzyme inhibitors (ACEIs) and or angiotensin 
II receptors blockers (AIIRBs) along with good blood pressure control should be part of 
the therapeutic approach for all proteinuric patients with FSGS and should be considered 
the mainstay of therapy for patients with FSGS secondary to conditions associated with 
hyperfiltration  and/or  reduced  nephron  mass  and  those  patients  with  nonnephrotic 
primary  FSGS.  For  nephrotic  patients  with  primary  FSGS,  recent  experience  has 
provided a note  of optimism in the use of immunosuppressive agents in  treating this 
otherwise progressive glomerulopathy.
A course of steroid therapy in primary FSGS is warranted in nephrotic patients 
with  reasonably well  preserved renal  function  (serum creatinine  levels  ≤3  mg/dL)  in 
whom it is not otherwise contraindicated. As an initial approach to treatment in adults, 
prednisone is given at a dose of 1 mg/kg/d (up to 80 mg) for 3 to 4 months. In the elderly 
(≥60 y), an initial alternate-day regimen of prednisone (1-2 mg/kg up to 120 mg) for 4 to 
5 months may be prudent. In patients showing a response to treatment (ie, a remission or 
a ≥50% reduction in proteinuria), the dose can be slowly tapered over an additional 3 
months. For patients unresponsive to the  initial course of therapy, a more rapid taper, 
over 4 weeks, should be used to minimize further steroid exposure. Steroids should be 
avoided  in  patients  with  familial  FSGS or  FSGS secondary  to  hyperfiltration  and/or 
reduced nephron mass.
One differentiating factor, with corticosteroid treatment of adults,65  is response to 
therapy. Pei et al63 found that only 42% of nephrotic adults with primary FSGS received 
treatment as compared with 95% of children. However, over the past 20 years a more 
optimistic experience has emerged with complete remission rates in excess of 30% being 
reported in over 80% of studies, with the majority showing complete remission rates of 
40% or greater. The most obvious difference among studies was the duration of therapy 
because the initial dose of prednisone used was similar. The total duration of therapy in 
those  studies  with  a  poor  response  rate  was  2  months  or  less  (low-dose  therapy) 
compared with an average of 5 to 9 months (high-dose therapy) in studies achieving high 
remission rates. Ponticelli et al59 reported a complete remission in only 15% of patients 
treated with steroids for less than 4 months, whereas 61% of patients treated for 4 months 
or more entered a complete remission. Rydel et al64 found that, in addition to a longer 
overall course of treatment (5 versus 3 mo), those patients achieving a remission had 
received an initial period of high-dose prednisone (≥60 mg/d) for a significantly longer 
duration than nonresponders (median time of 3 versus 1 mo, respectively).  Thus,  the 
initial duration of high-dose treatment may be as important as the overall duration of 
therapy.  Less than one third of adults  who achieve a complete remission do so by 8 
weeks of therapy. The median time to complete remission is 3 to 4 months, with the 
majority of patients reaching a complete remission by 5 to 9 months from the beginning 
of  treatment.4,23,63 Based  on  this  experience,  it  has  now  been  proposed  that  steroid 
resistance in adults be defined as the persistence of the nephrotic syndrome after a 4-
month trial of therapy with prednisone at a dose of 1 mg/kg/d. 
Cytotoxic  agents  along  with  steroids  have  been  used  as  initial  therapy  in 
approximately 20% of adults, but this appears to confer no added benefit in attaining a 
complete remission when compared with steroids alone. However, their use may induce a 
more stable remission than steroids alone. 
There  are  essentially  no  data  regarding  the  use  and/or  benefit  of  steroids  in 
nonnephrotic patients with primary FSGS. Owing to the more favorable course in these 
patients  a  more  conservative  approach  is  preferable  and  consider  steroid  only if  the 
patient becomes nephrotic. 
Familial forms of FSGS are known to be steroid resistant and thus, steroids are of 
little value in these patients. In patients with secondary FSGS caused by hyperfiltration 
and/or reduced nephron mass (especially in patients with obesity), steroids have no place 
in the management of these patients and should be avoided because the risk would be 
greater  than  any  potential  benefit.  Additionally,  they  may  exacerbate  the  underlying 
disease  (particularly in  obesity-related  FSGS) and accelerate  the  progression of  renal 
disease. 
In children, Arbus et al noted 3 clinical patterns after corticosteroid treatment of 
FSGS. Those who responded to steroids fared well, but those who never responded, or 
who developed resistance to treatment within 18 months, had a poorer prognosis. Other 
factors associated with greater likelihood of progression include hypertension, interstitial 
inflammation  and  fibrosis, or  African-American  or  Hispanic  ethnicity.  Massive 
proteinuria has been associated with progression of steroid-resistant nephrotic syndrome, 
although the pathogenetic significance of the proteinuria remains unresolved. 
Ponticelli  et  al.66 have  performed the  prospective  trial  in  which  patients  were 
randomized  to  cyclosporine  (CSA)  or  supportive  therapy  only.  Their  definition  of 
resistant was, however, only 6 weeks of prednisone therapy. Their age group was mixed, 
with both children and adults included in the study. They received CSA for 6 months at 
full  dose  and  in  those  that  had  either  a  partial  or  complete  remission  the  drug  was 
continued but the dose was tapered to zero over 6 months. Fifty-seven percent of their 
treated patients  had either a partial  or complete remission and approximately 40% of 
these  were  still  in  remission  at  2  years  of  follow-up  evaluation  although  the  details 
separating  their  FSGS  from  their  minimal  change  patients  was  incomplete  in  the 
published  article.  The  highest  rate  of  remission  was  in  a  recent  study by Lee  et  al. 
However, the level of evidence was only 4, given that it was a descriptive study and there 
were only 5 patients with the biopsy specimen-proven diagnosis of FSGS. Even in this 
group with 80% initial remission, relapse was high at 50% after 1 year off drugs.
Al-Lehbi et al67 administered mycophenolate (MMF) to 10 patients with FSGS 
who  were  resistant  to  steroids  and  were  either  cyclosporine  dependent  or  resistant. 
Patients received MMF 1.5-2 g/d plus prednisone for a total of 6 months. There was only 
a mild decrease of proteinuria from 12.6 to 10.8 g/d. All patients were still nephrotic at 
the end of treatment. Matalon et  al68 administered MMF to 11 adults with FSGS and 
nephrotic syndrome, at a mean dose of 1,275 mg/d, for a mean period of 28 weeks. The 
treatment induced a reduction in proteinuria from 6.8 to 5.7 g/d, which was statistically 
significant but of little clinical relevance. In no patients did proteinuria decrease to a level 
below 2.5 g/d.
Choi et al69 reported the outcome for 18 patients with FSGS dependent or resistant 
to  corticosteroids  or  cyclosporine,  or  with  progressive  renal  insufficiency.  Twelve 
patients had renal insufficiency and 9 had nephrotic syndrome. These patients received 
MMF at initial doses of 1 to 1.5 g/d for at least 3 months, plus variable doses of steroids 
in 12 of them. The 24-hour urine protein to creatinine ratio significantly decreased from 
2.7  to  0.8  (median  48%) at  the  end of  the  MMF treatment.  Among the  9 nephrotic 
patients  1  had  a  complete  remission  and  4  had  a  partial  remission.  Median  serum 
creatinine level increased from 1.9 to 2.2 mg/dL. In the 12 patients receiving concomitant 
steroid therapy, prednisone could be stopped completely without relapse in 8 cases. One 
patient relapsed and steroid treatment was resumed, and 3 others continued on low-dose 
steroid treatment. MMF generally was well tolerated
Ginsburg and Dau70 obtained a dramatic decrease in proteinuria, from 8.8 to 2.0 g/
24 hr, and in serum creatinine level, from 2.9 to 1.0 mg/dL, in an adult patient with 
resistant  FSGS  and  severe  nephrotic  syndrome,  treated  for  18  months  with  weekly 
plasmapheresis combined with moderate doses of prednisone and azathioprine. Mitwalli 
et  al71  reported  the  outcome  of  11  adult  patients  with  FSGS  resistant  to  prolonged 
immunosuppression who were treated with plasmapheresis in a mean of 17 sessions over 
a period of 15 to 25 weeks, in combination with oral prednisolone 60 to 80 mg daily, and 
intravenous cyclophosphamide,  5  to  10 mg/kg monthly,  for  6  months.  Eight  patients 
responded to plasmapheresis with a stabilization of renal function, associated with a long-
lasting  complete  remission  in  6  patients  (54.5%)  and  a  partial  remission  in  2  other 
patients  (18.2%).  The  remaining  3  patients  who  did  not  respond  to  plasmapheresis 
developed progressive renal insufficiency and 2 of them reached end-stage renal failure. 
No severe side effects were noted in any of the studied patients. Feld et al72  treated 8 
steroid-resistant  adults  with  6  plasmapheresis  sessions  over  2  weeks.  Proteinuria 
decreased  in  2  patients,  although  only  transiently  in  1  of  the  2  patients.  Both  the 
responders had stable renal function at the last follow-up evaluation. In contrast, 4 of the 
6 nonresponders had a progressive decline of renal function or were receiving dialysis 
treatment.  No  relationship  between  the  circulating  permeability  factor  and  the 
development  of  remission  was  observed.  Haas  et  al73  assessed  the  effects  of 
immunoadsorption on proteinuria and the predictive value of the permeability factor in 
serum  measured  with  glomerular  volume  variation  in  5  adults  with  FSGS. 
Immunoadsorption  reduced proteinuria  by more  than  50% in  2  of  5  patients.  In  one 
responder  the glomerular  volume variation  test,  which  was positive before  treatment, 
became  negative  after  the  first  immunoadsorption  cycle.  The  other  4  patients  had 
negative  glomerular  volume  variation  test  results  both  before  and  after 
immunoadsorption.
Kidney transplantation is associated with 2 problems that are relatively specific 
for FSGS. One of these is recurrence related to the presence of a circulating factor that 
enhances  glomerular  permeability.74  In  children  with  FSGS  in  whom  pre-emptive 
transplantation  has  been  attempted  to  avoid  hemodialysis,  a  very  high  incidence  of 
perioperative complications has been noted. These have been attributed to graft loss from 
thrombosis and may represent an effect of the nephrotic state rather than of FSGS per se. 
For this reason, most pediatric centers now choose to dialyse all children with FSGS for a 
period of time before proceeding to  transplant,  using either  coagulation studies  or an 
index of  active nephrosis  such as  lipid abnormalities  or  serum albumin to  determine 
whether the likelihood of thrombotic complications has diminished.   
Aims:
 
1.  To  identify  risk  factors  at  diagnosis  associated  with  progression  of  adult 
primary focal and segmental glomerulosclerosis 
2. To determine survival rates based on the factors identified
The biopsy reports and case records of all patients with FSGS (n=574) diagnosed at the 
Christian  Medical  College  Vellore  between  January  1994  to  December  2003  were 
reviewed. The criteria that define primary FSGS are (1) A lesion involving only some of 
the glomeruli in the biopsy with others remaining uninvolved (2) the involved glomeruli 
having a segment that has undergone collapse of capillaries with obliteration of capillary 
lumen with or without adhesion and (3) no pathologic evidence for primary disease that 
might produce secondary sclerosis (i e immune complex mediated glomerulopathy). 64
Inclusion Criteria:
a. Patient with Primary focal and segmental glomerulosclerosis
b. Age ≥16 years
c. With ≥ 3 months of follow up after diagnosis 
d.  Glomerular  filtration  rate  (GFR) by Modification  of  Diet  in  Renal  Disease 
(MDRD) formula of ≥ 10 ml / min at presentation.
Exclusion Criteria:
a.  Patients  with  evidence  of  systemic  disease,  other  disease  associated  with 
glomerulopathy, or a history of vesicouretric reflux, nephrectomy, solitary kidney, 
or intravenous drug abuse
b. Age < 16 years 
c. GFR (by MDRD) < 10ml/min at presentation   
d. Follow-up of < 3 months.
Among the secondary condition which lead to FSGS, 39 patients had history of 
prolonged  hypertension  before  developing  proteinuric  illness,  5  patients  had  renal 
agenesis, 5 patients had underlying vesicoureteric reflux, 2 patients were morbidly obese 
and 4 patients had past history of nephrectomy were excluded. 
Based on these criteria,  a total of 343 patients were identified and formed the 
basis of the present study.
Study design:
Patients were first divided into two groups based on the amount of proteinuria at 
the  time  of  presentation,  n=182,  with  proteinuria  ≥3  grams  per  day  and  n=161, 
proteinuria <3 grams per day. Nephrotic patients were subdivided on the basis of their 
serum albumin. Group 1 (n=117, with serum albumin <2.5 gram per dl) and Group 2 (n= 
65, with serum albumin ≥2.5 grams/dl).  Groups 1 and 2 were further analysed on the 
basis of their decline in GFR as progressor (≥10 ml/min/year) and non-progressor (<10 
ml/min/year).
Clinical Parameters:
Clinical  and  laboratory reports  were  collected  for  each  patient  at  the  time  of 
presentation. Nephrotic range proteinuria was defined as ≥3 gm/24 hours. Non nephrotic 
patients  had  proteinuria  <3  gm/24  hours.  Hypoalbuminemia  was  defined  as  serum 
albumin of <2.5 gm/dl.  Hematuria was defined as >5 red blood cells  per high-power 
field. Patients diastolic blood pressure ≥90 mm of Hg or a systolic blood pressure ≥140 
mm  of  Hg  were  considered  hypertensive.  Renal  failure  has  been  defined  as  GFR 
(MDRD) <60 ml/min and GFR <10ml/min or the need of renal replacement therapy has 
been taken as end stage renal disease.
Histopathological Parameters:
In addition to histopathological diagnosis  of FSGS the other features recorded 
were  proportion  of  glomeruli  with  segmental  scars  and  or  global  scars.  In  addition 
specific histopathological changes such as mesangial hypercellularity, interstitial fibrosis, 
tubular atrophy and vascular involvement were evaluated according to semi-quantitative 
methods as absent, mild to moderate and severe. The immunofluorescence study included 
the following antisera conjugated with fluorescein isothiocyanate: IgG, IgM, IgA, C3. 
For logistic regression analysis, absent and mild was given a value of 0, and moderate to 
severe, a value of 1.
Statistical Analyses:
Between  group  comparisons  for  continuous  variables  independent  t-test  for 
normal data and Mann Whitney test for non-normal data were used. Pearson Chi-Square 
test was used for categorical variables. Logistic regression analysis (step-wise method) 
was carried out to find the factors associated with progression in both the groups (1A vs 
1B and 2A vs 2B). Multivariate analyses were done on the factors whose Univariate 
logistic regression test had a p value of <0.25. Renal survival was calculated using the 
Kaplan-Meier method, and compared by Log rank test.  All analyses were carried out 
using SPSS version 11.5.
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Table  1  summarises  the  demographic  profile  of  343  patients  at  the  time  of 
diagnosis.  The  population  was  predominantly  male  (76.4%)  and  the  mean  age  at 
presentation was 35.3 (±13) years. At presentation nephrotic range proteinuria was seen 
in 53.1% patients while 40.5% had microscopic hematuria, 64.1% had hypertension and 
62.4% had renal failure. The mean serum creatinine and 24 hour urine protein were 2.0 
(±1.2) mg per dl and 4.3 (±3.9) grams per day respectively. The mean duration from 
onset of symptoms to renal biopsy was 17.2 (± 17.1) months and the duration of follow-
up ranged from 3 to 120 months with a mean duration of 21.5 (±19.9) months. 
Table 1:  Demographic profile at diagnosis     n=343 
Group 1B
Non-progressor
ΔGFR<10ml/min/yr
(n=64)
Group 2A
Progressor
ΔGFR≥10ml/min/yr
(n=23)
    Figure 1- Study design
Variable % Mean ± SD Median (range)
Males 76.4
Nephrotic syndrome 53.1
Hypertension 64.1
Micro hematuria 40.5
Renal failure (GFR<60ml/min) 62.4
Age (years) 35.3±13 35 (16 – 77)
Duration of follow up (months) 21.5±19.9 12 (3 – 120)
MAP (mmHg) 103.5±12 103.3 (70 – 167)
Serum creatinine (mg/dl) 2.0±1.2 1.7 (0.6 – 6.5)
24 hr urine protein gm/d 4.3±3.9 3.2 (0.04 – 23.1)
Serum albumin (gm/dl) 3.0±1.2 3.3 (0.9-5.2)
Serum cholesterol (mg/dl) 297.6±167.2 236 (90-1200)
GFR  (ml / min) at presentation 55.0±32.6 47.1 (10.1 – 125)
Nephrotic and Non-nephrotic Patients (Table 2):
Nephrotic range proteinuria was seen in 53.1% patients. Nephrotic patients were 
significantly  younger  as  compared  with  the  non-nephrotic  patients  (32.7±13.7  vs 
38.2±11.4 years; p=0.000) and had significantly better renal function at presentation as 
compared  to  non-nephrotic  (serum  creatinine  1.9±1.1  vs  2.2±1.2  mg/dl;  p=0.013). 
Nephrotic and non-nephrotic patients were similar with respect to gender, hypertension, 
hematuria,  and  duration  of  follow-up.  Although  the  rate  of  decline  in  GFR  was 
significantly higher in nephrotic patients as compared to non-nephrotic (7.1±36 vs 2.1±26 
ml/min/year; p=0.000), the mean GFR of nephrotic patients at the time of presentation 
was significantly higher as compared to non-nephrotic patients (61.9±33.3 vs 47.3±30.2 
ml/min; p=0.000). It was noticed that the interval from the onset of symptoms to renal 
biopsy  was  significantly  less  in  nephrotic  as  compared  with  non-nephrotic  patients 
(14.8±15.6 vs 19.9±18.3 months; p=0.000).
Comparison of Histology:
The  number  of  patients  having  moderate  to  severe  tubular  atrophy  (36.3  vs 
24.2%;  p=0.016)  and interstitial  fibrosis  (36.8 vs  24.2%;  p=0.012)  were significantly 
higher in nephrotic patients as compared to non nephrotic.
Table 2:  Clinical, laboratory findings and histopathological 
characteristics at biopsy: nephrotics vs non-nephrotics
Variable NephroticN=182
Non-nephrotic
N=161 p
Age (years) 32.7±13.7 38.2±11.4 0.000
Males ( % of patient ) 80.8 71.4 NS
Duration of symptoms(months) 14.8±15.6 19.9±18.3 0.000
Follow-up (months) 20.5±21.4 22.7±19.1 NS
Hypertension(%) 60.4 68.3 NS
Mean arterial pressure (mm of Hg) 102.4±11.7 104.7±12.3 NS
Urine protein (gms/day) 7.1±3.5 1.2±0.8 0.000
Micro hematuria (%) 45.1 35.4 NS
Scr at presentation (mg%) 1.9±1.1 2.2±1.2 0.013
GFR at presentation (ml/min) 61.9±33.3 47.3±30.2 0.000
Renal failure at presentation(%) 51.1 75.2 0.000
Decline in GFR (ml/min/yr) 7.1±36 2.1±26 0.000
Serum albumin (gm/dl) 2.4±1.0 3.8±0.8 0.000
Serum cholesterol (mg/dl) 377.7±168.9 219.1±122.9 0.000
Segmental sclerosis (>50%) 9.9 6.2 NS
Moderate and severe interstitial 
fibrosis (%) 36.8 24.2 0.012
Tubular atrophy (%) 36.3 24.2 0.016
Vascular involvment (%) 52.2 64.6 NS
IgM deposition (%) 50.5 35.4 0.005
C3 deposition (%) 53.8 52.2 NS
Univariate analyses of factors associated with progression in nephrotic 
patients with low albumin (Subgroup 1A, 1B) (Table-3):
Risk factors for progression by univariate analysis in nephrotic patients with low 
albumin at  diagnosis  included the amount  of  proteinuria  per day (9.0±2.6 vs 7.0±4.1 
grams  per  day;  p=0.000)  and  moderate  to  severe  tubular  atrophy (56.6% vs  23.4%; 
p=0.000) and interstitial fibrosis (66.0% vs 18.8%; p=0.000)
Univariate analyses of factors associated with progression in nephrotic 
patients with normal albumin (Subgroup 2A, 2B) (Table-3):
Risk  factors  for  progression  by  univariate  analysis  in  nephrotic  patients  with 
normal albumin group at diagnosis included amount of proteinuria per day (7.7 ±.2.7 vs 
4.7±2.3)  grams per day;  p=0.000)  and moderate  to  severe tubular  atrophy (52.2% vs 
21.4%;p=0.011) and interstitial fibrosis (60.9% vs 14.3%;p=0.000)
Table 3: Clinical, laboratory findings and histolopathological 
characteristics of nephrotic patients at biopsy: progressor vs non-
progressor
Variable Subgroup 1A( n=53)
Subgroup 
1B(n=64) p
Subgroup 
2A(n=23)
Subgroup 
2B(n=42) p
Age (years) 33.1±16.7 33.1±13.9 NS 30.1±11.1 33.0±10.4 NS
Males (% of patient ) 73.6 85.9 NS 82.6 81.0 NS
Duration of symptoms till 
biopsy (months) 11.0±11.1 19.6±20.9 0.000 7.7±4.7 16.1±12.5 0.000
Follow-up (months) 17.7±15.4 22.2±26.1 NS 17.1±16.8 23.2±22.3 NS
Hypertension (%) 54.7 56.3 NS 69.6 69.0 NS
MAP (mm of Hg) 101.9±14.0 101.7±9.8 NS 103.3±13.9 103.7±9.8 NS
24 hours urine protein 
(gms/day) 9.0±2.6 7.0±4.1 0.000 7.7 ±.2.7 4.7±2.3 0.000
Microhematuria (%) 41.4 51.6 NS 60.9 31.0 NS
S cr at presentation 1.4±0.6 2.1±1.2 0.001 1.6±1.1 2.1±1.3 NS
Renal failure at 
presentation (%) 35.8 62.5 0.004 39.1 59.5 NS
GFR at presentation 
(ml/min) 71±28.7 55.6±33.7 0.005 70.9±35.1 55.0±34.5 NS
S cholesterol (mg/dl) 454±160.5 448.4±149 NS 297.5±170 234±61.3 NS
Segmental sclerosis (>50%) 13.2 7.8 NS 13.0 7.1 NS
Moderate and severe 
interstitial fibrosis (%) 66.0 18.8 0.000 60.9 14.3 0.000
Tubular atrophy (%) 56.6 23.4 0.000 52.2 21.4 0.011
Vascular involvment (%) 45.3 50.0 NS 65.2 57.1 NS
IgM deposition (%) 52.8 50.0 NS 56.5 45.2 0.025
C3 deposition (%) 43.4 53.1 NS 47.8 64.3 NS
Multivariate  Logistic  regression  analyses  of  factors  associated  with 
progression:
Risk  factors  for  progression  by multivariate  analysis  in  nephrotic  patients  with  low albumin 
(table-4) at diagnosis (group 1A,1B) included amount of proteinuria (β 0.001), and moderate to severe 
interstitial  fibrosis (Odds Ratio 8.5 ).  In  nephrotic  patients  with normal  albumin (table-5)  at  diagnosis 
(group 2A,2B), the amount of proteinuria (β 0.001), and moderate to severe interstitial fibrosis (Odds Ratio 
6.1) were significant risk factors.
Table 4: Multivariate analysis of prognostic factors: low 
albumin (group 1)
Variable β Oddsratio
95.0 % C.I.
Lower        Upper p value
Proteinuria 0.001 1.000 1.000 1.100 0.041
Interstitial fibrosis 2.141 8.504 3.377 21.417 0.000
Renal failure at 
presentation -1.275 0.279 0.113 0.694 0.006
Constant -1.495 0.224 0.013
                        All factors satisfied 25 % level of significance in Univariate analysis
Table 5: Multivariate analysis of prognostic factors: normal 
albumin (group 2)
Variable β Oddsratio
95.0 % C.I.
Lower        Upper p value
Proteinuria 0.001 1.000 1.000 1.001 0.004
Interstitial fibrosis 1.824 6.198 1.635 23.498 0.007
Constant -3.563 0.028 0.000
       
All factors satisfied 25 % level of significance in Univariate analysis
Multivariate analysis of risk factors for progression to ESRD (logistic 
regression model) (Table 6):
A multivariate analysis examined the risk factors for progression to ESRD of the entire nephrotic 
cohort (both low and normal albumin) as compared with the non-nephrotic cohort. Patients with moderate 
to  severe  interstitial  fibrosis  had  the  highest  risk  of  progression  (Odds  Ratio  8.3;95%  CI  4.6,15.0). 
Nephrotics  with  low albumin  have  higher  risk of  progression (Odds  Ratio  4.3;  95% CI 2.2,8.3)  than 
nephrotics with normal albumin (Odds Ratio 3.1;95% CI 1.4,6.9). Renal failure at presentation did not 
emerge as a risk factor for progression (O 0.3;95% CI 0.1,0.6).
Table 6: Multivariate analysis of risk factors for progression to ESRD: 
(Logistic regression model)
Factors β SE Exp(B)
95.0% CI
Lower   Upper p
Nephrotic+Low albumin 1.46 0.33 4.32 2.23      8.37 0.000
Nephrotic+Normal albumin 1.15 0.39 3.17 1.46      6.90 0.003
Moderate and severe interstitial 
fibrosis 2.12 0.30 8.36  4.64      15.05 0.000
Renal failure at presentation -1.07 0.30 0.34 0.19      0.61 0.000
Constant -1.97 0.33 0.13 0.000
Renal Survival Rates:
Kaplan-Meier analysis showed that cumulative probability of renal survival from 
the onset of symptoms was 105 months (95% CI; 91,120). Mean renal survival for the 
patient in the progressor category was significantly low (48 months, 95% CI; 38,58 ) as 
compared with the patients in non-progressor category (122 months, 95% CI; 110,134 
p=< 0.001).
The  mean  renal  survival  in  patients  who  had  moderate  to  severe  interstitial 
fibrosis is significantly low as compared to absent or mild interstitial fibrosis (49 and 133 
months: p=<0.0001). Patients with no risk factors (proteinuria and interstitial fibrosis) 
had  a  mean  renal  survival  time of  90  (95% CI:84,97)  months  while  the  mean  renal 
survival time in those with both risk factors were 46 (95% CI:35,57, p=0.002) months.
In all, 44 patients (12.8%) had reached ESRD at last follow-up.
Figure  2  -  Cumulative  probability  of  renal  survival  vs  risk  factors: 
progressor vs non-progressor
Figure 3 - Cumulative probability of renal survival: nephrotic vs non- 
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Figure  4  -  Cumulative  probability  of  renal  survival  vs  risk  factors: 
degree of interstitial fibrosis
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Figure 5 - Cumulative probability of renal survival : additive risk
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Primary FSGS is  a  major cause of proteinuria and nephrotic  syndrome in adults,  the 
etiology of which is largely unknown. There are very few reported studies on adult FSGS 
from India.65,75
In the study by Agarwal et al65, 65 adults with biopsy proven FSGS were followed 
(mean duration 32 months). Nephrotic syndrome (81%) was the commonest mode of 
presentation. All patients received steroids for an average duration 8-12 weeks before a 
response to steroid is clearly catergorised. Complete and partial remission developed in 
31% and 27% of the cases, respectively. They concluded that response to steroids can not 
be predicted clinically at the time of presentation and all patients should be given one 
course of steroids as patients who respond to steroids have better long term survival. 
Pokhariyal et al75 in a retrospective analysis  of  93 adult patients with biopsy 
proven FSGS followed up for a mean duration of 12.6 months, showed that hypertension, 
hematuria and degree of proteinuria did not significantly affect the response to steroid 
therapy.  Univariate  logistic  regression  analysis  showed  that  the  significant  factors 
predictive of remission were duration of steroid therapy, serum creatinine at onset and 
presence of interstitial fibrosis (>25%) at initial biopsy. Multivariate logistic regression 
analysis showed that the only factor predictive of remission was steroid therapy duration 
>16 weeks. They concluded that patients with idiopathic FSGS required treatment for at 
least 16 weeks, before labeling them as steroid non-responsive. Patients with interstitial 
fibrosis (>25%) have a significantly poor response to therapy.
 In this study we analysed a large cohort of adult patients of primary FSGS with 
regard to the natural course, renal survival and the risk factors that affect it. 
Nephrotic range proteinuria was seen in 53.1 percent of patients at the time of 
presentation which is comparable with that reported by Cattran et al.23 and York et al 
(55%)76. Although hypertension (64.1%) was the commonest mode of presentation in our 
cohort, nephrotic syndrome was the commonest mode of presentation in the two studies, 
Agarwal  et  al  (81%) and Pokhariyal  et  al  (59%) reported from India.  This  could be 
because 62.4% of our patients  had renal  failure  at  presentation compared to  19% by 
Agarwal et al and 26% by Pokhariyal et al.
The nephrotic patients were significantly younger at presentation.  At the time of 
presentation, nephrotics had higher GFR as compared to non-nephrotic patients but the 
rate of decline in GFR was significantly higher in nephrotics. The time from the onset of 
symptoms  to  presentation  was  significantly  shorter  in  the  nephrotics.  The  nephrotics 
presented earlier with oedema when they still had better preserved renal function.
 Even among nephrotics, analysed on the basis of serum albumin at diagnosis, the 
amount of proteinuria and the degree of interstitial fibrosis and tubular atrophy on biopsy 
are  the  significant  risk  factors  for  progression.  None  of  the  other  histopathological 
characteristics like percentage of glomeruli with segmental sclerosis, degree of mesangial 
hypercellularity, degree of vascular involvement, degree of IgM or C3 deposits predicted 
progression, as has been shown earlier5.
On multivariate analysis, factors independently predictive of outcome were the 
amount  of proteinuria  and the degree of  interstitial  fibrosis  in  both groups as  shown 
earlier5.  Rydel  et  al64 and  Pei  et  al57 were  unable  to  demonstrate  proteinuria  as  an 
independent predictor of progression perhaps due to the unusually high rate of remission 
in  their  treated  nephrotic  patients.  However  when patients  entering  a  remission  were 
eliminated from their multivariate analysis, proteinuria became prognostically significant. 
Contrary to other studies, renal failure at presentation was not a predictor of progression 
to  ESRD in our  cohort.  This  is  because the high risk nephrotics  presented earlier  as 
swelling appeared even when the renal function was preserved. 
The  10  year  renal  survival  was  60% which  is  in  concordance  with  previous 
reports from the west.2,5,23 
This study confirms that tubulointerstitial fibrosis and amount of proteinuria as 
significant risk factors for the progression of primary FSGS in adults.  However renal 
failure at presentation was offset by the rapidly progressing nephrotic patients presenting 
earlier and with preserved renal function. 
In this study therapeutic response has not been taken into account since only the 
risk  factors  at  presentation  are  examined.  Studies  have  confirmed  that  a  therapeutic 
response  by  prolonged  course  of  steroids  with  remission  of  proteinuria  changes  the 
natural history of FSGS.4,7 However, some studies have shown that therapeutic response 
can’t  be  predicted  at  presentation7,64 and  uniform protocol  with  careful  follow-up  is 
required to document comparable remission rates.
Conclusions: 
1. Clinical and pathological indicators help to predict renal failure in adult primary FSGS at the 
time of presentation.
2. Independent predictors of disease progression are
a. amount of proteinuria
b. degree of interstitial fibrosis
3. Independent predictors of development to ESRD in adult primary FSGS are
a. nephrotic range proteinuria
b. low serum albumin 
c. degree of interstitial fibrosis
4. Renal failure at presentation is not a predictor of progression could be because of high risk 
nephrotics presented earlier as swelling appeared even when the renal function was preserved.
5. This study predict the probability of renal survival in adult primary FSGS at presentation 
and therefore identify high risk group.
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